CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | MOCHEL, Jonathan | |
hal.structure.identifier | Mayo Clinic [Rochester] | |
dc.contributor.author | EKKER, Stephen | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | JOHANNES, Chad | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | JERGENS, Albert | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | ALLENSPACH, Karin | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | BOURGOIS-MOCHEL, Agnes | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | KNOUSE, Michael | |
hal.structure.identifier | Modélisation Mathématique pour l'Oncologie [MONC] | |
dc.contributor.author | BENZEKRY, Sébastien | |
hal.structure.identifier | Iowa State University [ISU] | |
dc.contributor.author | WIERSON, Wesley | |
hal.structure.identifier | National Cancer Institute [Bethesda] [NCI-NIH] | |
dc.contributor.author | LEBLANC, Amy | |
hal.structure.identifier | Mayo Clinic [Rochester] | |
dc.contributor.author | KENDERIAN, Saad | |
dc.date.accessioned | 2024-04-04T03:01:26Z | |
dc.date.available | 2024-04-04T03:01:26Z | |
dc.date.issued | 2019-05 | |
dc.identifier.issn | 1550-7416 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/192901 | |
dc.description.abstractEn | The advent of the genome editing era brings forth the promise of adoptive cell transfer usingengineered chimeric antigen receptor (CAR) T-cells for targeted cancer therapy. CAR T-cellimmunotherapy is probably one of the most encouraging developments for the treatment ofhematological malignancies. In 2017, two CAR T-cell therapies were approved by the U. S Food andDrug Administration; one for the treatment of pediatric Acute Lymphoblastic Leukemia (ALL), the otherfor adult patients with advanced lymphomas. However, despite significant progress in the area, CART-cell therapy is still in its early days and faces significant challenges, including the complexity andcosts associated with the technology. B-cell lymphoma is the most common hematopoietic cancer indogs, with an incidence approaching 0.1% and a total of 20-100 cases per 100,000 individuals. It is awidely accepted naturally occurring model for human non-Hodgkin’s lymphoma. Current treatment iswith combination chemotherapy protocols, which prolong life for less than a year in canines and areassociated with severe dose-limiting side effects, such as gastrointestinal and bone marrow toxicity.To date, one canine study generated CAR T-cells by transfection of mRNA for CAR domainexpression. While this was shown to provide a transient anti-tumor activity, results were modest,indicating that stable, genomic integration of CAR modules is required in order to achieve lastingtherapeutic benefit. This Commentary summarizes the current state of knowledge on CAR T-cellimmunotherapy in human medicine and its potential applications in animal health, while discussingthe potential of the canine model as a translational system for immuno-oncology research. | |
dc.language.iso | en | |
dc.publisher | American Association of Pharmaceutical Scientists | |
dc.subject.en | Immuno-Oncology | |
dc.subject.en | CAR T-cell | |
dc.subject.en | Lymphoma | |
dc.subject.en | One Health | |
dc.title.en | CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies | |
dc.type | Article de revue | |
dc.identifier.doi | 10.1208/s12248-019-0322-1 | |
dc.subject.hal | Sciences du Vivant [q-bio]/Cancer | |
dc.subject.hal | Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie | |
bordeaux.journal | AAPS Journal | |
bordeaux.volume | 21 | |
bordeaux.hal.laboratories | Institut de Mathématiques de Bordeaux (IMB) - UMR 5251 | * |
bordeaux.issue | 3 | |
bordeaux.institution | Université de Bordeaux | |
bordeaux.institution | Bordeaux INP | |
bordeaux.institution | CNRS | |
bordeaux.peerReviewed | oui | |
hal.identifier | hal-02099159 | |
hal.version | 1 | |
hal.popular | non | |
hal.audience | Internationale | |
hal.origin.link | https://hal.archives-ouvertes.fr//hal-02099159v1 | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=AAPS%20Journal&rft.date=2019-05&rft.volume=21&rft.issue=3&rft.eissn=1550-7416&rft.issn=1550-7416&rft.au=MOCHEL,%20Jonathan&EKKER,%20Stephen&JOHANNES,%20Chad&JERGENS,%20Albert&ALLENSPACH,%20Karin&rft.genre=article |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |